Dr. Olivier Mignen and his colleagues in France have discovered and patented monoclonal antibodies (mAbs) targeting plasma membrane STIM1 as a means of controlling calcium entry. They are looking for partners, i.e. investors (VC = venture capitalists), who are willing to fund further development of the mAbs towards therapeutic approval so the mAbs can be used for treating cancers and/or autoimmune diseases. Typically partners put up money in exchange for some small percentage of ownership, perhaps a percentage of royalties from the expected future drug sales. It sounds like they would like to start up a small company dedicated towards this development and they will consider different ways of funding the company. I think this is a very promising and exciting opportunity to have new therapeutics for these diseases.